Generali Investments Management Co LLC Acquires 1,468 Shares of Amgen Inc. $AMGN

Generali Investments Management Co LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.3% during the second quarter, HoldingsChannel reports. The fund owned 9,966 shares of the medical research company’s stock after purchasing an additional 1,468 shares during the quarter. Amgen comprises about 0.8% of Generali Investments Management Co LLC’s investment portfolio, making the stock its 27th biggest holding. Generali Investments Management Co LLC’s holdings in Amgen were worth $3,609,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. E. Ohman J or Asset Management AB grew its position in shares of Amgen by 6.1% in the second quarter. E. Ohman J or Asset Management AB now owns 19,515 shares of the medical research company’s stock valued at $7,067,000 after purchasing an additional 1,130 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Amgen by 15.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 346,596 shares of the medical research company’s stock valued at $125,509,000 after purchasing an additional 47,052 shares during the period. City Holding Co. lifted its holdings in Amgen by 4.0% during the 2nd quarter. City Holding Co. now owns 12,282 shares of the medical research company’s stock worth $4,447,000 after purchasing an additional 470 shares in the last quarter. Orrstown Financial Services Inc. lifted its holdings in Amgen by 11.6% during the 2nd quarter. Orrstown Financial Services Inc. now owns 3,129 shares of the medical research company’s stock worth $1,133,000 after purchasing an additional 325 shares in the last quarter. Finally, Charles Schwab Trust Co boosted its stake in Amgen by 678.3% in the 2nd quarter. Charles Schwab Trust Co now owns 7,464 shares of the medical research company’s stock worth $2,703,000 after purchasing an additional 6,505 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on AMGN shares. BMO Capital Markets lifted their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research report on Friday, June 5th. Guggenheim boosted their price objective on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research note on Monday. Finally, Sanford C. Bernstein upped their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $371.68.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $417.20 on Tuesday. The company’s fifty day moving average price is $364.54 and its 200-day moving average price is $357.03. The firm has a market capitalization of $225.55 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 3.82 and a beta of 0.41. Amgen Inc. has a one year low of $269.77 and a one year high of $418.40. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the company posted $6.02 EPS. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.